This research article explores the potential link between nucleoside reverse transcriptase inhibitors (NRTIs), medications used for HIV and hepatitis B, and a reduced risk of Alzheimer's disease (AD). The authors hypothesize that NRTIs' ability to inhibit inflammasome activation, a process implicated in AD, contributes to this protective effect. Through a retrospective analysis of two extensive health insurance databases—the United States Veterans Health Administration and MarketScan—the study found a significantly lower incidence of AD in individuals exposed to NRTIs. The findings suggest a rationale for further clinical trials to investigate inflammasome inhibitors, like NRTIs or their less toxic derivatives, as potential treatments for AD.